IHC Marker-CD105 Test: Booking, Price, and Results
About IHC Marker-CD105 Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | Endoglin, ENG, Tumour Angiogenesis Marker, Microvessel Density (MVD) Marker |
| Sample Type | Formalin-fixed, paraffin-embedded (FFPE) tissue block |
| Fasting Required | No |
| Report Time | 3 days |
| Recommended For | All ages and genders; typically ordered for patients with suspected or diagnosed solid tumours |
| Price | Starting at ₹1,920 |
What is an IHC Marker-CD105 Test?
The IHC marker-CD105 test is a specialised laboratory test that detects the presence of the CD105 protein (Endoglin or ENG) in tissue samples. It uses immunohistochemistry (IHC), a technique that applies antibodies to tissue sections to make specific proteins visible under a microscope. Doctors typically order this test after a biopsy or surgery to assess blood vessel activity within and around a tumour. It is also known by its alternate names: Endoglin, ENG, and Tumour Angiogenesis Marker.
What Does an IHC Marker-CD105 Test Measure?
This test analyses tissue samples to detect two key indicators of tumour blood vessel activity. The table below summarises what is measured.
| Parameter | What It Tells Us |
|---|---|
| CD105/Endoglin Protein Expression | Detects whether the CD105 protein is present on blood vessel cells in the tissue; reported as positive or negative with intensity scoring |
| Microvessel Density (MVD) | Counts the number of small blood vessels (microvessels) per microscopic field; higher counts indicate greater new blood vessel formation in and around the tumour |
CD105 is a protein found on the surface of cells that line blood vessels. It is highly active in vessels that are forming inside tumours and shows little to no activity in the blood vessels of normal, healthy tissue. Measuring MVD (Microvessel Density) using CD105 immunohistochemistry is the accepted standard method for quantifying tumour angiogenesis (the formation of new blood vessels that feed a tumour).
Why is an IHC Marker-CD105 Test Done?
A pathologist or oncologist may request this test when evaluating a tissue biopsy to understand the behaviour and aggressiveness of a tumour.
Common Symptoms That May Require This Test
The following symptoms, when investigated further, may lead a doctor to order a biopsy and subsequent IHC testing including the CD105 Endoglin marker.
- Unexplained weight loss without a clear cause
- Persistent and unusual fatigue
- A suspicious lump or mass detected on imaging
- Abnormal bleeding from any site
- Chronic pain localised to a specific area
- Swollen lymph nodes
- Changes in bowel or bladder habits
Conditions This Test Can Help Detect
CD105 expression has been studied across a wide range of tumours. This test may support assessment or prognosis in the following conditions.
- Brain, breast, colon, lung, and stomach cancers, where CD105 is expressed on tumour blood vessels
- Colorectal, endometrial, breast, prostate, and non-small cell lung cancers, where high CD105 expression has been linked to poorer outcomes
- Clear cell renal cell carcinoma, gastric carcinoma, oesophageal adenocarcinoma, pancreatic carcinoma, and ovarian cancer
- Arteriovenous malformation (AVM), an abnormal connection between arteries and veins
- Hereditary haemorrhagic telangiectasia type 1 (HHT1), an inherited vascular disorder caused by mutations in the CD105 gene
How to Prepare and What to Expect
Because this test is performed on a tissue sample collected during a biopsy or surgery, the preparation process differs from a routine blood test.
Do You Need to Fast?
No fasting is required. This test is not performed on blood, so there are no dietary restrictions before sample collection. However, if your biopsy procedure itself requires anaesthesia, your surgical team will provide separate instructions.
Practical Tips Before Your Test
The following steps will help ensure the test proceeds smoothly.
- Bring a detailed clinical history including your symptoms, previous test results, and family history, as this is required for the test
- Carry all previous biopsy reports and imaging results to share with the laboratory
- Inform your doctor about any ongoing treatments, especially chemotherapy or radiation therapy, as these may affect results
- Ensure your tissue sample is handled and transported correctly; ask your surgical team about proper specimen packaging
- Carry a valid doctor's prescription, as this is required before the test can be performed
Step-by-Step Procedure
The following steps describe how the tissue sample is collected and processed for the IHC marker-CD105 test.
- A small piece of tissue is removed during a biopsy or surgical procedure performed by your doctor or surgeon.
- The tissue is immediately preserved using formalin (a preserving fluid) and then embedded in paraffin wax to create a firm block. This is called an FFPE block.
- In the laboratory, very thin slices of the tissue block are cut using a precision instrument called a microtome and placed onto glass slides.
- The slides undergo a process called heat-induced epitope retrieval to prepare the tissue, followed by the application of specialised antibodies that bind specifically to the CD105 protein.
- A detectable marker (such as an enzyme or coloured dye) attached to the antibody makes the CD105 protein visible under a microscope.
- A trained pathologist examines the stained slides, identifies CD105 staining patterns, and counts the number of microvessels to calculate microvessel density.
Factors That Can Affect Accuracy
The following factors may influence the reliability of test results.
- Poor tissue fixation: Inadequate preservation of the biopsy sample can interfere with protein detection
- Processing delays: A long gap between biopsy collection and fixation may alter protein structure
- Prior treatment: Chemotherapy or radiation therapy received before the biopsy may change how proteins are expressed
- Sample age and tissue type: Older stored specimens or certain tissue types may produce variable staining patterns
- Tumour heterogeneity: Different areas within the same tumour may show different staining patterns
Understanding Your IHC Marker-CD105 Test Results
Results of this test are interpreted by a qualified pathologist alongside other clinical and pathological findings. The table below provides a general guide to what results may indicate.
| Result | Typical Interpretation |
|---|---|
| CD105 Expression: Negative | Little to no CD105 staining; consistent with normal or non-angiogenic tissue |
| CD105 Expression: Positive (low to moderate) | Some blood vessel activity; interpretation depends on tumour type and context |
| CD105 Expression: Positive (high) | Active tumour angiogenesis; often associated with more aggressive tumour behaviour and, in many cancer types, a less favourable prognosis |
| MVD: Higher count | Greater new blood vessel formation within the tumour; in many cancers, higher MVD correlates with shorter survival |
| MVD: Lower count | Less active neovascularisation; may reflect different tumour biology depending on cancer type |
These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain circumstances can affect how results are interpreted.
Prior chemotherapy or radiation therapy can alter CD105 protein expression in tissue, meaning results from treated samples may not reflect the original tumour biology. Tissue fixation quality and the time elapsed between collection and processing can significantly affect staining outcomes. Tumour heterogeneity means that different sections of the same tumour may show varying CD105 staining patterns, which a pathologist will account for during analysis.
How to Maintain Healthy Levels
While CD105 results reflect tumour biology rather than a modifiable lifestyle marker, the following general habits support overall health.
- Eat a balanced diet rich in fruits, vegetables, and antioxidants, and maintain a healthy body weight through regular physical activity
- Avoid known risk factors such as tobacco use and excessive alcohol consumption
- Attend regular medical check-ups to support early detection of any health concerns
Lupin Diagnostics IHC Marker-CD105 Test Price
The IHC marker-CD105 test is priced starting at ₹1,920 at Lupin Diagnostics. This test requires a visit to a Lupin Diagnostics centre; home collection is not available for this test, as it requires a tissue sample obtained through a biopsy or surgical procedure.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 1920 |
| CHENNAI | 1920 |
| HYDERABAD | 1920 |
| KOLKATA | 1920 |
| NAVI MUMBAI | 1920 |
| PUNE | 1920 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
- Select the IHC marker-CD105 test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample submission.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
The IHC marker-CD105 test is used to assess tumour angiogenesis, which is the formation of new blood vessels that supply a tumour. It helps pathologists evaluate how aggressively a tumour is growing and provides prognostic information. Results are used alongside other clinical and pathological findings to guide cancer management.
The test uses a tissue sample collected during a biopsy or surgical procedure. The sample is fixed in formalin and embedded in paraffin wax to form an FFPE block, which is then sent to the laboratory for analysis. This is not a blood test and cannot be performed from a blood sample.
No fasting or dietary changes are required. You should bring your complete clinical history, all previous biopsy reports, and a valid doctor's prescription. Inform your doctor about any chemotherapy or radiation treatment you may have received, as this can influence results.
Results for the CD105 Endoglin IHC test are typically available within 3 days at Lupin Diagnostics. Turnaround times may vary slightly depending on the complexity of the case and the number of markers being assessed simultaneously.
A positive result means the CD105 protein is present on blood vessel cells within the tissue sample, indicating active angiogenesis. In many cancer types, high tumour angiogenesis marker expression and elevated MVD (Microvessel Density) are associated with more aggressive tumour behaviour. Your pathologist and treating doctor will explain what the result means in your specific case.
Endoglin (CD105) expression has been studied in a wide range of solid tumours, including breast, colorectal, lung, prostate, stomach, and brain cancers, among others. Its prognostic significance can vary depending on the cancer type, so a qualified pathologist will always interpret results within the full clinical context.
Clinical history helps the pathologist interpret CD105 staining accurately. Information about previous treatments, the type and site of the tumour, and other test results allows for more precise analysis and a clinically meaningful report. Providing complete records at the time of sample submission is strongly recommended.
IHC Marker-CD105 Test: Booking, Price, and Results
